Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019063802) ANTI IGF, ANTI PD-1 ANTI-CANCER COMBINATION THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/063802 International Application No.: PCT/EP2018/076494
Publication Date: 04.04.2019 International Filing Date: 28.09.2018
IPC:
A61K 39/395 (2006.01) ,A61K 38/17 (2006.01) ,C07K 16/22 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
22
against growth factors
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173 55216 INGELHEIM AM RHEIN, DE
Inventors:
WEYER-CZERNILOFSKY, Ulrike; DE
RESCHKE, Markus; DE
Agent:
SIMON, Elke Anna Maria; DE
WOLFRAM, Dr. Markus; DE
Priority Data:
17194196.629.09.2017EP
Title (EN) ANTI IGF, ANTI PD-1 ANTI-CANCER COMBINATION THERAPY
(FR) POLYTHÉRAPIE ANTICANCÉREUSE ANTI-IGF, ANTI PD-1
Abstract:
(EN) The disclosure relates to the combined use of certain anti-IGF antibody molecules with PDl antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such anti-IGF antibody molecules and antagonists.
(FR) L'invention concerne l'utilisation combinée de certaines molécules d'anticorps anti_IGF avec des antagonistes PD1 pour le traitement du cancer. L'invention concerne en outre des compositions pharmaceutiques et des kits comprenant de telles molécules d'anticorps anti_IGF et des antagonistes.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)